| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51dd67b82710b7c2bfc8c17885613c87 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-109
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2019-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b68a9a03b8c8b952c18e068d89a0771
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0acdfb440ed87ff054f63f0680238e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c472457ebcd9f48fb0810fc1184c5142 |
| publicationDate |
2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3768707-A1 |
| titleOfInvention |
Compositions and methods for modified b cells expressing reassigned biological agents |
| abstract |
Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules. |
| priorityDate |
2018-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |